OraSure Technologies (NASDAQ: OSUR) announced in a Securities and Exchange Commission Form 4 filing that President and Chief Executive Officer Carrie Eglinton Manner purchased 22,022 shares of the company’s common stock on March 13, 2026.
The shares were acquired at a weighted average price of $2.9985 per share, with individual transaction prices spanning from $2.93 to $3.12. The aggregate value of the trade was $66,032. After the purchase, Eglinton Manner directly holds 2,158,574 shares of OraSure Technologies.
The filing states the transaction was executed pursuant to a pre-arranged Rule 10b5-1 trading plan that the executive adopted on November 29, 2025. The 10b5-1 framework allows insiders to sell or buy company stock according to a plan established when they are not in possession of material nonpublic information.
Market context for the move includes a year-to-date share-price advance of 29% for OSUR. An InvestingPro analysis referenced in company reporting indicates that OSUR appears undervalued at current levels. An InvestingPro Tip also notes an active program of share repurchases by management, and that there are 10 additional tips available to subscribers.
On the operational front, OraSure Technologies reported fourth-quarter 2025 revenue of $26.8 million, a figure that fell short of the consensus expectation of $28.08 million, missing by approximately 4.6%. The company said gross margins improved despite the revenue shortfall.
OraSure continues to operate in an environment characterized by funding constraints and ongoing operational losses, according to its recent disclosures. Management highlighted prospects for growth tied to product launches scheduled for 2026. No analyst upgrades or downgrades were disclosed in the company's recent reporting. Investor sentiment remains cautious in light of the firm's current financial performance and forward-looking plans.
Clear summary
OraSure CEO Carrie Eglinton Manner bought 22,022 shares for $66,032 under a Rule 10b5-1 plan. The company posted Q4 2025 revenue of $26.8 million, missing expectations by roughly 4.6% while reporting improved gross margins and preparing product launches for 2026. Independent analysis noted the stock appears undervalued and management has been buying back shares.